Mineralys Therapeutics, Inc. (MLYS) · Nov 4, 2026 · Earnings
Miss — EPS loss $0.64 vs ~$0.55 consensus
Mineralys earnings missed the modest quarterly loss expected, while new lorundrostat analyses and launch preparation keep the FDA decision story intact.
Mineralys is a pre-commercial biotech approaching the December 22, 2026 FDA decision for lorundrostat, with launch preparation and funding already expected to carry operations into 2028. Its prior quarter had already established that commercial infrastructure was being built ahead of the decision, so this filing is mainly about fresh efficacy detail and execution—not a change in the regulatory timetable.
The quarter missed the modest loss expected. Reported loss per share was $0.64 versus published consensus of roughly $0.55, while the $57.3 million net loss widened from $36.9 million a year earlier. The miss is partly a consequence of the company moving toward commercialization: G&A rose sharply as it expanded personnel and professional support, while R&D spending fell as major clinical work wound down.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| EPS (Financial results) | $(0.64) | $(0.52) | $(0.55) |
| Net loss (Financial results) | $(57.3)M | $(36.9)M | |
| R&D expense (Financial results) | $22.7M | $31.5M | |
| G&A expense (Financial results) | $37.4M | $9.7M | |
| Cash, equivalents and investments (Balance sheet) | $624.7M | $656.6M* |
*December 31, 2025 comparison.
The more important business update was constructive clinical evidence. New Launch-HTN analysis showed 46% of patients on the 50 mg dose reached the guideline systolic blood-pressure target below 130 mmHg at Week 12, and more than two-thirds reduced systolic pressure by at least 10 mmHg. 〔0〕 This strengthens the commercial usefulness story, although it does not remove the remaining FDA approval risk.
The filing adds support in the kidney-disease opportunity but not a new regulatory catalyst. Blood-pressure reductions were consistent across CKD stages, and albuminuria fell 52% versus placebo; meanwhile, the PDUFA date remains unchanged and launch preparations are described as advancing. 〔1〕
Cash remains adequate for the stated launch plan, but spending is shifting toward commercialization. Cash and investments declined to $624.7 million from $656.6 million at year-end, while the company added a $98.3 million senior secured term loan. The runway into 2028 is therefore intact on management's assumptions, but the higher G&A base means the business is now entering a more expensive pre-launch phase. 〔2〕
The board departure is non-operational and low significance. Derek DiRocco will resign effective December 31, 2026, and the filing explicitly says the decision was not due to disagreement with the company or management. 〔3〕
Bottom line: The quarter itself missed expectations, but the underlying lorundrostat launch story remains intact and gained useful efficacy detail. This is a mildly constructive business update, not a rewrite of the investment case: the December 22 FDA decision remains the decisive next event.
FDA PDUFA decision for lorundrostat, December 22, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!